Biosimilars in oncology: current and future perspectives
Journal Title: Generics and Biosimilars Initiative Journal - Year 2013, Vol 2, Issue 2
Abstract
Cancer represents a significant, and growing, burden on healthcare systems. This is driven, at least in part, by escalating cancer drug budgets. Loss of patent protection on biopharmaceuticals enables the development and production of similar biological medicines, or biosimilars. Biosimilars are currently available for use in oncology in the supportive care setting; the focus of biosimilar development is likely to switch to agents such as monoclonal antibodies. Available evidence indicates that biosimilars approved by regulatory authorities offer a safe and effective alternative to originator biological therapies. They also offer potentially significant cost savings to healthcare payers. The greater affordability of biosimilars may also result in clinical benefits, through earlier and wider appropriate therapy use and release of funding to be used elsewhere in clinical care. Greater adoption of biosimilars represents a key approach to reducing healthcare expenditure and improving patient access to important treatments.
Authors and Affiliations
Matti Aapro
Keywords
Related Articles
- EP ID EP355024
- DOI 10.5639/gabij.2013.0202.023
- Views 112
- Downloads 0
Myths, questions, facts about generic drugs in the EU
Many generic drugs are now being prescribed and the trend is increasing. For example, in Austria, the number of all generics prescriptions has more than doubled from 11% in 2000 to 23% in 2010. However, many myths and qu...
Current status of biopharmaceuticals in Iran’s pharmaceutical market
The clinical importance of biopharmaceuticals for the management of life threatening diseases is increasing but costs have become a major obstacle to the administration of these medicines, especially in resource limited...
Alternative statistical strategies for biosimilar drug development
Introduction: Many regulatory authorities have published requirements for the approval of biosimilar medicinal products. However, there is no guidance on which quantitative standards should be used to define how similar...
Innovator companies should focus on innovations
Despite biopharmaceuticals having an enormous potential value for our health, they have also become a serious threat to our healthcare systems.
Biosimilars naming, label transparency and authority of choice – survey findings among European physicians
Introduction: A survey of the views of European physicians on familiarity of biosimilar medicines has demonstrated the need for distinguishable non-proprietary names to be given to all biologicals. Methods: The Alliance...